Archives
-
CUDC-907: Dual PI3K and HDAC Assay Guide
2026-09-24
CUDC-907 is a dual PI3K and HDAC inhibitor for cell-based studies that need to examine PI3K/AKT signaling pathway inhibition alongside histone deacetylase (HDAC) inhibition. It is intended for controlled scientific research, not diagnostic, clinical, or therapeutic use; confirm assay conditions in the selected model rather than treating the listed working condition as universally validated.
-
Lipid Peroxidation (MDA) Assay Kit in Liver Injury
2026-09-24
The Lipid Peroxidation (MDA) Assay Kit can help connect lipid oxidation to ferroptosis-related liver injury—but MDA is most informative when interpreted alongside orthogonal measurements. This article examines a doxorubicin liver-injury study and shows how to use MDA as a mechanistic readout rather than a stand-alone diagnosis.
-
Everolimus (RAD001) Cancer Research Workflows
2026-09-23
Build more interpretable mTOR studies with Everolimus (RAD001), from pathway-confirming assays to time-resolved measurements of growth arrest and cell death. This guide connects practical handling, cancer cell proliferation inhibition, apoptosis assay design, and translational model selection.
-
FAISL–FAK Proteolysis in TNBC
2026-09-22
The 2024 Advanced Science study identifies FAISL as a long noncoding RNA that stabilizes focal adhesion kinase by blocking Calpain 2-mediated proteolysis, thereby promoting triple-negative breast cancer progression and metastasis. Its integration of transcriptomic analysis, RNA–protein interaction mapping, functional assays, patient data, and nanoparticle-mediated silencing defines a post-transcriptional regulatory axis with potential value for TNBC research.
-
Nanocarrier-Mediated dsRNA Penetration of Insect Cuticle
2026-09-22
This study proposes a mechanistic explanation for how star cationic polymer nanocarriers help double-stranded RNA cross the insect cuticle. Its evidence connects dsRNA complexation, improved surface wetting, wax dissolution, and reduced chitin-layer resistance, providing a framework for designing noninvasive transdermal RNA interference systems.
-
Phenylalanine Nanostructures Sensitize ICB
2026-09-21
This Nature Nanotechnology study shows that metal-ion-chelating l-phenylalanine nanostructures can activate dendritic cells and improve immune checkpoint blockade responses in breast and colorectal tumour models. Its central innovation is the combination of ion-channel modulation with short-term starvation, which enhances nanostructure uptake, reverses selected immunosuppressive features, and strengthens tumour-specific cytotoxic T-cell activity.
-
Septin4, VHL, and HIF-1α in Cardiac Hypoxia
2026-09-21
The reference study identifies HIF-1α as a previously unrecognized Septin4-interacting protein in hypoxia-stressed cardiomyocytes. Its data support a mechanism in which Septin4 strengthens VHL-dependent ubiquitination and degradation of HIF-1α, thereby worsening apoptosis and refining how oxygen-sensing pathways may be studied in cardiac injury.
-
2X HyperFusion™ High-Fidelity Master Mix for CRISPR
2026-09-20
Discover how the 2X HyperFusion High-Fidelity Master Mix can strengthen PCR validation in CRISPR-enabled cancer research. This guide connects a bufalin–CRISPR nanomedicine study with practical decisions about fidelity, blunt ends, controls, and assay interpretation.
-
Cell Cycle Assay Kit K2263: PI Flow Cytometry
2026-09-19
The Cell Cycle Assay Kit K2263 measures DNA content by propidium iodide staining for cell cycle progression analysis. It distinguishes cell cycle phases G0/G1, S, and G2/M and supports sub-G1 assessment, while DNA content alone cannot separate G2 from M or prove apoptosis.
-
CGP 55845 hydrochloride in Synaptic Assays
2026-09-19
Use CGP 55845 hydrochloride to separate GABAB receptor signaling from astrocytic GAT-3-driven effects in dentate gyrus and other in vitro preparations. This practical guide combines receptor pharmacology, electrophysiology, neurotransmitter release modulation, and troubleshooting strategies without extending the evidence into unsupported clinical or in vivo claims.
-
Baicalin Methyl Ester: Intestinal Barrier Workflows
2026-09-18
Baicalin methyl ester is an esterified derivative of baicalin designed for mechanistic studies of LPS-induced intestinal barrier damage. Its value comes from connecting cytokine suppression with MLCK and tight-junction readouts in MODE-K cells and mouse models.
-
Cisplatin and the Pyroptosis Frontier
2026-09-17
Cisplatin is more than a DNA-damaging benchmark: emerging evidence suggests that its cytotoxic outcome can include GSDME-associated pyroptosis alongside apoptosis. This thought-leadership guide translates that insight into practical strategies for mechanism-resolved assays, xenograft studies, and chemotherapy resistance research.
-
D-Luciferin for Glioma Bioluminescence Studies
2026-09-17
D-Luciferin converts firefly luciferase activity into a sensitive readout for reporter expression, intracellular ATP quantification, and longitudinal tumor burden assessment. Applied alongside the 2025 glioma soluble PD-L1 findings, it helps connect Wnt/β-catenin activity with tumor behavior while preserving the need for orthogonal immune and biomarker assays.
-
KDM4A as a Therapeutic Vulnerability in Mesothelioma
2026-09-17
The reference study identifies the histone lysine demethylase KDM4A as an essential growth regulator in malignant pleural mesothelioma (MPM), linking its elevated expression to tumor-cell survival, DNA repair, and replication-checkpoint biology. Genetic and pharmacologic experiments support KDM4A inhibition as a preclinical strategy and suggest enhanced activity when combined with navitoclax, prexasertib, or adavosertib.
-
25-Hydroxycholesterol Reprograms Tumor Macrophages
2026-09-16
Xiao et al. identify CH25H-derived 25-hydroxycholesterol as an immunometabolic checkpoint that links lysosomal sterol accumulation to AMPKα–STAT6 signaling and immunosuppressive macrophage function. The study provides a mechanistic framework for understanding how CH25H loss can improve T-cell activity and enhance anti-PD-1 responses in tumor models.